Anbio Biotechnology (NNNN)

Market Cap	2.17B
Revenue (ttm)	8.19M
Net Income (ttm)	2.37M
Shares Out	43.89M
EPS (ttm)	0.06
PE Ratio	899.52
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	132,174
Open	51.41
Previous Close	49.71
Day's Range	47.64 - 52.90
52-Week Range	5.18 - 55.65
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About NNNN

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Feb 19, 2025
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: NNNN
• Website: https://www.anbio.com

Financial Performance

In 2024, Anbio Biotechnology's revenue was $8.19 million, an increase of 21.95% compared to the previous year's $6.71 million. Earnings were $2.37 million, an increase of 5.29%.

Financial numbers in USD